GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Synthetic organic
Comment: The structure for tacaciclib was obtained from proposed INN list 129 (August 2023), where it is described as cyclin-dependent kinase inhibitor and antineoplastic agent. The structure is calimed in patent WO2022130304A1, for potential to treat cancer or other proliferative diseases that are mediated by CDK7 [1]. Interogation of online information suggests that this compound may be XL102 (formerly AUR102), an orally bioavailable covalent CDK7 inhibitor that was acquired by Exelixis, from Aurigene, in late 2020.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| (2S)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-methyl-2-[3-[6-[[(E)-4-morpholin-4-ylbut-2-enoyl]amino]pyridin-3-yl]phenyl]butanamide |
Database Links ![]() |
|
| CAS Registry No. | 2768774-66-7 (source: WHO INN record) |
| GtoPdb PubChem SID | 485206001 |
| PubChem CID | 164533260 |
| Search Google for chemical match using the InChIKey | CVAXNGIXLUILFO-KPGJNUASSA-N |
| Search Google for chemicals with the same backbone | CVAXNGIXLUILFO |
| UniChem Compound Search for chemical match using the InChIKey | CVAXNGIXLUILFO-KPGJNUASSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | CVAXNGIXLUILFO-KPGJNUASSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖|
Tacaciclib (links to external site)
Cat. No. HY-156643 |